Cidara Therapeutics Invites You to Upcoming Investor Conferences
Cidara Therapeutics, Inc. (NASDAQ: CDTX), situated in San Diego, is excited to announce its participation in two notable investor conferences scheduled for November. Cidara is renowned for its innovative use of the Cloudbreak platform, a proprietary technology designed to develop drug-Fc conjugate (DFC) therapeutics.
Details of the Conferences
During these conferences, Cidara will have the opportunity to engage with investors and share insights into its latest developments. Below are the details of the events:
Guggenheim 2nd Annual Healthcare Innovation Conference
Date: November 11
Time: 8:00 AM ET
Format: Fireside Chat
Jefferies London Healthcare Conference
Date: November 17
Time: 4:30 PM GMT
Format: Presentation
Participants and attendees can access a live webcast from these events on Cidara's website in the Investors section. Additionally, replays will be available for a minimum of 30 days following the events.
One-on-One Meetings for Investors
In addition to the scheduled presentations, Cidara will also engage in one-on-one investor meetings during the conferences. This approach provides a unique opportunity for investors to gain a more in-depth understanding of Cidara's corporate strategies and clinical advancements.
About Cidara Therapeutics
Founded on the innovative Cloudbreak platform, Cidara Therapeutics is dedicated to exploring novel DFCs. These therapeutics combine targeted small molecules or peptides with a proprietary human antibody fragment, creating a cutting-edge approach in battling viral infections. One of Cidara’s flagship products, CD388, is a long-acting antiviral aimed at the universal prevention of influenza with a single dose, effectively inhibiting viral proliferation. Notably, in June 2023, CD388 received Fast Track Designation from the FDA, marking a significant milestone in its development.
Recent Advancements
Cidara Therapeutics continues to lead in the pharmaceutical space with positive developments. Recently, the company announced encouraging top-line results from its Phase 2b NAVIGATE trial, which took place within the past year. Furthermore, it initiated its Phase 3 ANCHOR trial, expanding the scope of its antiviral research.
As Cidara expands its technological capabilities, the company remains devoted to addressing unmet medical needs through its advanced therapeutics. With representatives at the forefront of investor engagement this coming November, the expectation is to communicate the significant progress that Cidara is making in the realm of drug development.
Contact Information
Investor Contact:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
Email: britchie@lifesciadvisors.com
Media Contact:
Michael Fitzhugh
LifeSci Communications
Email: mfitzhugh@lifescicomms.com
Frequently Asked Questions
What is the Cloudbreak Platform?
The Cloudbreak platform is a proprietary technology utilized by Cidara Therapeutics to develop innovative drug-Fc conjugate therapeutics.
What is CD388?
CD388 is Cidara's leading antiviral candidate, designed to provide long-lasting protection against influenza infections with a single dosage.
How does Cidara engage with investors?
Cidara connects with investors through conferences, one-on-one meetings, and webcasts that provide insights into the company's progress and advancements.
What recent trials has Cidara completed?
Recently, Cidara completed the Phase 2b NAVIGATE trial and has initiated the Phase 3 ANCHOR trial to further develop its antiviral candidates.
Where can I find more information about Cidara Therapeutics?
For detailed information, visit Cidara's official website at www.cidara.com.
